Effects of BCG-PSN on the Levels of Inflammatory Factors and Th1/Th2 Differentiation in Chronic Spontaneous Urticaria: Meta-Analysis and Systematic Review

IF 3.7 4区医学 Q1 DERMATOLOGY

Dermatologic Therapy Pub Date : 2023-09-15 DOI:10.1155/2023/2917144

Qiang Fu, Fu-Jun Huang, Zi-Wenyan Zhou, Lei Tang, Qi Zheng, Miao Zhang, Xun Zhou

{"title":"Effects of BCG-PSN on the Levels of Inflammatory Factors and Th1/Th2 Differentiation in Chronic Spontaneous Urticaria: Meta-Analysis and Systematic Review","authors":"Qiang Fu, Fu-Jun Huang, Zi-Wenyan Zhou, Lei Tang, Qi Zheng, Miao Zhang, Xun Zhou","doi":"10.1155/2023/2917144","DOIUrl":null,"url":null,"abstract":"Background. Bacillus Calmette–Guerin polysaccharide nucleic acid (BCG-PSN), as an immune modulator, can effectively regulate the immune function of the body, control the release of histamine inflammatory substances, and achieve allergic effects against chronic spontaneous urticaria (CSU). This study aimed to evaluate the effectiveness of BCG-PSN on the levels of inflammatory factors and Th1/Th2 differentiation in CSU. Methods. A systemic literature search of BCG-PSN treatment of CSU was performed using the PubMed, Cochrane Library, Web of Science, CBM, and other databases. A quantitative meta-analysis was conducted according to the guidelines of the Cochrane Handbook. Review manager software 5.4 was used for meta-analysis. Results. Twenty-seven studies pertaining to 2840 patients were included. The duration of treatment was 4 to 12 weeks. BCG-PSN can increase CD3+T levels (MD = 6.06; 95% CI: 5.30 to 6.82; <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M1\"> <mi>p</mi> </math> < 0.00001; I2 = 31%), CD4+T levels (MD = 5.41; 95% CI: 4.82 to 6.01; <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M2\"> <mi>p</mi> </math> < 0.00001; I2 = 40%), and CD4+/CD8+(MD = 0.33; 95% CI: 0.28 to 0.38; <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M3\"> <mi>p</mi> </math> < 0.00001; I2 = 15%); at the same time, BCG-PSN can downregulate CD8+T levels (MD = −3.28; 95% CI: −3.82 to −2.74; <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M4\"> <mi>p</mi> </math> < 0.00001; I2 = 32%). Furthermore, BCG-PSN could downregulate IL-4 levels (MD = −4.06, 95% CI: −5.15 to −2.97, <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M5\"> <mi>p</mi> </math> < 0.00001; I2 = 0%), TNF-α levels (MD = −2.34; 95% CI: −3.01 to −1.66; <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M6\"> <mi>p</mi> </math> < 0.00001; I2 = 26%) and upregulate IL-10 levels (MD = 25.59, 95% CI: 23.50 to 27.69, <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M7\"> <mi>p</mi> </math> < 0.00001; I2 = 0%) and INF-γ levels (MD = 4.62, 95% CI: 3.79 to 5.45, <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M8\"> <mi>p</mi> </math> < 0.00001; I2 = 5%). Conclusions. BCG-PSN can regulate the levels of inflammatory factors and Th1/Th2 differentiation in CSU. However, the long-term effectiveness and more objective experimental indicators of BCG-PSN remain to be further studied. Trial Registration. This trial is registered with PROSPERO ID: CRD42022332475.","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"66 1","pages":"0"},"PeriodicalIF":3.7000,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatologic Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2023/2917144","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background. Bacillus Calmette–Guerin polysaccharide nucleic acid (BCG-PSN), as an immune modulator, can effectively regulate the immune function of the body, control the release of histamine inflammatory substances, and achieve allergic effects against chronic spontaneous urticaria (CSU). This study aimed to evaluate the effectiveness of BCG-PSN on the levels of inflammatory factors and Th1/Th2 differentiation in CSU. Methods. A systemic literature search of BCG-PSN treatment of CSU was performed using the PubMed, Cochrane Library, Web of Science, CBM, and other databases. A quantitative meta-analysis was conducted according to the guidelines of the Cochrane Handbook. Review manager software 5.4 was used for meta-analysis. Results. Twenty-seven studies pertaining to 2840 patients were included. The duration of treatment was 4 to 12 weeks. BCG-PSN can increase CD3+T levels (MD = 6.06; 95% CI: 5.30 to 6.82;

p

< 0.00001; I2 = 31%), CD4+T levels (MD = 5.41; 95% CI: 4.82 to 6.01;

p

< 0.00001; I2 = 40%), and CD4+/CD8+(MD = 0.33; 95% CI: 0.28 to 0.38;

p

< 0.00001; I2 = 15%); at the same time, BCG-PSN can downregulate CD8+T levels (MD = −3.28; 95% CI: −3.82 to −2.74;

p

< 0.00001; I2 = 32%). Furthermore, BCG-PSN could downregulate IL-4 levels (MD = −4.06, 95% CI: −5.15 to −2.97,

p

< 0.00001; I2 = 0%), TNF-α levels (MD = −2.34; 95% CI: −3.01 to −1.66;

p

< 0.00001; I2 = 26%) and upregulate IL-10 levels (MD = 25.59, 95% CI: 23.50 to 27.69,

p

< 0.00001; I2 = 0%) and INF-γ levels (MD = 4.62, 95% CI: 3.79 to 5.45,

p

< 0.00001; I2 = 5%). Conclusions. BCG-PSN can regulate the levels of inflammatory factors and Th1/Th2 differentiation in CSU. However, the long-term effectiveness and more objective experimental indicators of BCG-PSN remain to be further studied. Trial Registration. This trial is registered with PROSPERO ID: CRD42022332475.

查看原文本刊更多论文

BCG-PSN对慢性自发性荨麻疹炎症因子水平和Th1/Th2分化的影响:荟萃分析和系统评价

背景。卡介苗多糖核酸(BCG-PSN)作为一种免疫调节剂，可有效调节机体免疫功能，控制组胺类炎症物质的释放，达到对慢性自发性荨麻疹(CSU)的过敏作用。本研究旨在评价BCG-PSN对CSU炎症因子水平及Th1/Th2分化的影响。方法。使用PubMed、Cochrane Library、Web of Science、CBM等数据库对BCG-PSN治疗CSU进行系统文献检索。根据Cochrane手册的指南进行定量荟萃分析。采用Review manager软件5.4进行meta分析。结果。纳入了27项研究，涉及2840例患者。治疗时间为4 ~ 12周。BCG-PSN可提高CD3+T水平(MD = 6.06;95% CI: 5.30 ~ 6.82;p & lt;0.00001;I2 = 31%)， CD4+T水平(MD = 5.41;95% CI: 4.82 ~ 6.01;p & lt;0.00001;I2 = 40%)， CD4+/CD8+(MD = 0.33;95% CI: 0.28 ~ 0.38;p & lt;0.00001;I2 = 15%);同时，BCG-PSN可下调CD8+T水平(MD =−3.28;95% CI:−3.82 ~−2.74;p & lt;0.00001;I2 = 32%)。此外，BCG-PSN可下调IL-4水平(MD = - 4.06, 95% CI: - 5.15 ~ - 2.97, p <0.00001;I2 = 0%)， TNF-α水平(MD = - 2.34;95% CI:−3.01 ~−1.66;p & lt;0.00001;I2 = 26%)和上调IL-10水平(MD = 25.59, 95% CI: 23.50 ~ 27.69, p <0.00001;I2 = 0%)和INF-γ水平(MD = 4.62, 95% CI: 3.79 ~ 5.45, p <0.00001;I2 = 5%)。结论。BCG-PSN可调节CSU炎症因子水平及Th1/Th2分化。但BCG-PSN的远期疗效及更客观的实验指标有待进一步研究。试验注册。该试验注册为PROSPERO ID: CRD42022332475。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Dermatologic Therapy 医学-皮肤病学

CiteScore

7.00

自引率

8.30%

发文量

711

审稿时长

3 months

期刊介绍： Dermatologic Therapy has been created to fill an important void in the dermatologic literature: the lack of a readily available source of up-to-date information on the treatment of specific cutaneous diseases and the practical application of specific treatment modalities. Each issue of the journal consists of a series of scholarly review articles written by leaders in dermatology in which they describe, in very specific terms, how they treat particular cutaneous diseases and how they use specific therapeutic agents. The information contained in each issue is so practical and detailed that the reader should be able to directly apply various treatment approaches to daily clinical situations. Because of the specific and practical nature of this publication, Dermatologic Therapy not only serves as a readily available resource for the day-to-day treatment of patients, but also as an evolving therapeutic textbook for the treatment of dermatologic diseases.